| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/21/2011 | US20110092506 Trisubstituted amine compound |
| 04/21/2011 | US20110092501 Novel inhibitors |
| 04/21/2011 | US20110092491 Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity |
| 04/21/2011 | US20110092487 Novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza-bicyclo[3.3.1]-nonane-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/21/2011 | US20110092486 Ih channel inhibitors for the promotion of wakefulness |
| 04/21/2011 | US20110092483 Screening molecules with anti-prion activity: kits, methods and screened molecules |
| 04/21/2011 | US20110092482 Methods and compositions |
| 04/21/2011 | US20110092478 Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting parp |
| 04/21/2011 | US20110092475 2-substituted-ethynylthiazole derivatives and uses of same |
| 04/21/2011 | US20110092474 Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor |
| 04/21/2011 | US20110092473 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| 04/21/2011 | US20110092464 Neurogenesis by modulating angiotensin |
| 04/21/2011 | US20110092463 Combination for use in the treatment of inflammatory disorders |
| 04/21/2011 | US20110092459 Alpha helix mimetics and methods relating thereto |
| 04/21/2011 | US20110092453 Treatments and prevention of hydrocephalus |
| 04/21/2011 | US20110092448 Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics |
| 04/21/2011 | US20110092447 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions |
| 04/21/2011 | US20110092436 Compounds for treating symptoms associated with parkinson's disease |
| 04/21/2011 | US20110092435 Treatment of parkinson's disease |
| 04/21/2011 | US20110092433 Fgf9-related methods for treating anxiety |
| 04/21/2011 | US20110091876 Zcytor19 polynucleotides, polypeptides, antibodies and methods of use |
| 04/21/2011 | US20110091585 Herbal compositions and methods for enhancing vital energy and athletic performance |
| 04/21/2011 | US20110091582 Method for Obtaining Concentrated Polyphenol Extracts From a Stirring Process |
| 04/21/2011 | US20110091579 Vitamin d2 enriched mushrooms and fungi for treatment of oxidative stress, alzheimer's disease and associated disease states |
| 04/21/2011 | US20110091576 Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growrh factors of stem cells |
| 04/21/2011 | US20110091566 Controlled release pharmaceutical compositions |
| 04/21/2011 | US20110091558 Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability |
| 04/21/2011 | US20110091547 Pharmaceutical Compositions Comprising Brivaracetam |
| 04/21/2011 | US20110091544 Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| 04/21/2011 | US20110091543 Oral delivery of modified transferrin fusion proteins |
| 04/21/2011 | US20110091542 Baclofen and r-baclofen gastroretentive drug delivery systems |
| 04/21/2011 | US20110091534 Compositions comprising polymeric micelles for drug delivery |
| 04/21/2011 | US20110091525 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 04/21/2011 | US20110091511 Transdermal delivery of drugs based on crystal size |
| 04/21/2011 | US20110091508 Oligofluorinated cross-linked polymers and uses thereof |
| 04/21/2011 | US20110091503 Therapeutic composition with a botulinum neurotoxin |
| 04/21/2011 | US20110091472 Compositions for treating psoriasis |
| 04/21/2011 | US20110091469 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 04/21/2011 | US20110091467 Compositions and methods for modulating dopamine neurotransmission |
| 04/21/2011 | US20110091464 Novel peptides and protein and uses thereof |
| 04/21/2011 | US20110091463 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | US20110091456 Treatment of neurological conditions |
| 04/21/2011 | US20110091450 Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| 04/21/2011 | US20110091448 Methods for regulation of stem cells |
| 04/21/2011 | US20110091446 Single domain antibodies capable of modulating bace activity |
| 04/21/2011 | US20110091444 Methods and compositions for treatment and prevention of major depressive disorder |
| 04/21/2011 | US20110091440 Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases |
| 04/21/2011 | US20110091434 Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase |
| 04/21/2011 | US20110091433 Treatment using reprogrammed mature adult cells |
| 04/21/2011 | US20110091431 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 04/21/2011 | US20110091411 Interleukin-1 Muteins Linked to Virus-Like Particles to Treat IL-1 Associated Diseases |
| 04/21/2011 | US20110091388 Use of pde7 inhibitors for the treatment of movement disorders |
| 04/21/2011 | US20110091382 Novel imaging agents for detecting neurological dysfunction |
| 04/21/2011 | US20110091379 Method for treating tumors and their metastases |
| 04/21/2011 | US20110091378 Methods and Compositions for Treating Fibrosis Related Disorders Using IL-17 Antagonists |
| 04/21/2011 | US20110091372 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | DE102009049679A1 Pyrazolopyrimidinderivate Pyrazolopyrimidinderivate |
| 04/21/2011 | CA2777843A1 Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors |
| 04/21/2011 | CA2777782A1 Sepiapterin reductase inhibitors for the treatment of pain |
| 04/21/2011 | CA2777752A1 Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide |
| 04/21/2011 | CA2777663A1 Method for treating chronic nerve tissue injury using a cell therapy strategy |
| 04/21/2011 | CA2777537A1 Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
| 04/21/2011 | CA2777518A1 Cgrp receptor antagonists |
| 04/21/2011 | CA2777305A1 Polymorphs of pardoprunox |
| 04/21/2011 | CA2777243A1 Use of a neuregulin to treat peripheral nerve injury |
| 04/21/2011 | CA2777010A1 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 04/21/2011 | CA2776835A1 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
| 04/21/2011 | CA2775959A1 Dual variable domain immunoglobulins and uses thereof |
| 04/20/2011 | EP2311954A1 Mutations in the Parkin gene, compositions, methods and uses |
| 04/20/2011 | EP2311949A2 Antisense compounds targeted to connexins and methods of use thereof |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311847A1 Composition containing stable vitamin B6 derivative |
| 04/20/2011 | EP2311836A1 Process for preparing naphthyridine derivatives. |
| 04/20/2011 | EP2311831A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| 04/20/2011 | EP2311830A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 04/20/2011 | EP2311828A1 Benzothiophene alkanol piperazine derivatives and their use as antidepressant |
| 04/20/2011 | EP2311824A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| 04/20/2011 | EP2311812A1 Method for chemical synthesis of oxcarbazepine |
| 04/20/2011 | EP2311807A1 Compounds and composition as protein kinase inhibitors |
| 04/20/2011 | EP2311806A2 Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
| 04/20/2011 | EP2311803A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| 04/20/2011 | EP2311802A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| 04/20/2011 | EP2311801A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2011 | EP2311799A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311798A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311797A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311796A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311496A1 A combination of morphine and oxycodone for use in the alleviation or prevention of pain |
| 04/20/2011 | EP2311494A1 Histone modification inhibitor specific to target gene |
| 04/20/2011 | EP2311484A1 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases |
| 04/20/2011 | EP2311483A1 GCSF for use in treating a neurological disease with pathophysiological mechanisms involving ischemia or hypoxia |
| 04/20/2011 | EP2311481A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| 04/20/2011 | EP2311472A1 Cognitive disorder-ameliorating agent |
| 04/20/2011 | EP2311465A1 Remedies for diseases to be applied to eye |
| 04/20/2011 | EP2311463A1 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 04/20/2011 | EP2311460A1 Oxymorphone controlled release formulations |
| 04/20/2011 | EP2311453A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| 04/20/2011 | EP2311451A1 Amino-methyl substituted tetracycline compounds |
| 04/20/2011 | EP2311450A1 Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of a Neurodegenerative Disease |
| 04/20/2011 | EP2311445A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |